On May 27, 2026 Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, reported that two abstracts featuring (Z)-endoxifen have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held May 29 to June 2, 2026 in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Both abstracts highlight the scientific rationale and ongoing clinical development of (Z)-endoxifen in ER-positive breast cancer," said Dr. Steven C. Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa Therapeutics. "Our preclinical data demonstrate that (Z)-endoxifen achieved robust estrogen receptor inhibition across clinically relevant ESR1 mutations associated with endocrine resistance, while the EVANGELINE trial is evaluating its potential in combination with ovarian function suppression in premenopausal women in the neoadjuvant setting. Together, these abstracts underscore our belief that (Z)-endoxifen has the potential to address important unmet needs across multiple treatment settings in ER-positive breast cancer."

Presentation details are as follows:

Session Type: Online Publication
Abstract Title: Effect of (Z)-endoxifen Demonstrates Robust Estrogen Receptor Signaling Inhibition Across Clinically Relevant ESR1 Mutations

Summary: The abstract highlights new preclinical data demonstrating that (Z)-endoxifen delivers robust ER inhibition across clinically relevant estrogen receptor alpha gene (ESR1) mutations. ESR1 mutations are a major mechanism of acquired endocrine resistance in ER-positive breast cancer and remain associated with limited treatment options despite the emergence of next-generation endocrine therapies. These data therefore support the ongoing clinical development of (Z)-endoxifen, as well as its potential as a promising treatment option for breast cancer patients with limited therapeutic alternatives.

Key Data Highlights

(Z)-endoxifen demonstrated robust dose-dependent and statistically significant inhibition of ER signaling across clinically relevant concentrations.
In parental MCF-7 breast cancer cells, ER activity was reduced to 16-26% of control (p < 0.001). In ESR1 wild-type models, studied therapies reduced ER signaling to <5% of control (p < 0.001).
(Z)-endoxifen maintained consistent ER inhibition across key ESR1 mutations (Y537N, Y537S, D538G) (p < 0.01).
Comparator oral Selective Estrogen Receptor Degraders (SERDs), including elacestrant and imlunestrant, showed reduced efficacy in ESR1-mutant settings, particularly in D538G, as compared to (Z)-endoxifen.
The D538G mutation demonstrated the highest resistance, while Y537N remained the most sensitive across treatments.
Session Type: Poster Presentation
Date: June 1, 2026, 1:30 PM-4:30 PM CT
Poster Board Number: 133b
Abstract Title: A Phase 2 Clinical Trial in Progress of (Z)-Endoxifen Plus Goserelin as Neoadjuvant Therapy in Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE)
Presenters: Dr. Steven C. Quay & Hayley Erickson

Summary: The abstract describes EVANGELINE (NCT05607004), an ongoing, multicenter, open-label Phase 2 study evaluating daily 40 mg (Z)-endoxifen plus goserelin administered every 28 days as neoadjuvant therapy in premenopausal women with ER+/HER2-negative, cT2-3, cN0-1 breast cancer.

Key Highlights

EVANGELINE is evaluating (Z)-endoxifen plus ovarian function suppression (OFS) as a neoadjuvant therapy in premenopausal women with ER+/HER2-negative, cT2-3, cN0-1 breast cancer.
The primary objective is to determine the proportion of patients with baseline Ki-67 >10% who achieve Ki-67 of 10% or less after 4 weeks of therapy.
A Simon two-stage design is being used to study whether, after four weeks, at least 65% of patients treated achieved a Ki-67 of 10% or less, with 20 patients enrolled in the first stage and, if promising, another 25 patients enrolled in the second stage (cohort A).
A parallel cohort of 20 patients with baseline Ki-67 of 10% or less (cohort B) is enrolled to assess objective response rate at 24 weeks per RECIST v1.1.
Secondary objectives include safety and tolerability, residual cancer burden, and PEPI score; correlative analyses include examining the effect of treatment on select tumor and plasma biomarkers.
A pharmacokinetic run-in phase has been completed and informed selection of (Z)-endoxifen 40 mg daily plus OFS for Phase 2 evaluation. Phase 2 enrollment opened in May 2025.
About ESR1-Mutant Breast Cancer

Mutations in ESR1 commonly arise in patients with advanced ER+ breast cancer following endocrine therapy and are associated with resistance to treatment. These mutations drive ligand-independent ER activation, leading to continued tumor growth despite standard therapies. Effective treatment options for ESR1-mutant disease remain limited.

About EVANGELINE

EVANGELINE (NCT05607004) is an ongoing, multicenter, open-label Phase 2 study evaluating (Z)-endoxifen plus goserelin as a neoadjuvant therapy in premenopausal women with ER+/HER2-negative, cT2-3, cN0-1 breast cancer. The study will characterize early antiproliferative activity, clinical response, safety and biologic effects of dual ER and PKCβ1/AKT pathway targeting in this setting.

(Press release, Atossa Therapeutics, MAY 27, 2026, View Source [SID1234666119])